Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Caelyx

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

NICE unveils long-awaited review of methodologies

Use of quality of life measures to be reviewed

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Lynparza scores approval for first line ovarian use in Europe

Partners plan further expansion

- PMLiVE

World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Ovarian cancer is the second most lethal gynaecological cancer worldwide. To raise awareness of this often fatal disease, our article looks at its symptoms, current treatments and future therapies.

Porterhouse Medical Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links